These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 31958292)

  • 1. EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies.
    Kiesewetter B; Cherny NI; Boissel N; Cerisoli F; Dafni U; de Vries EGE; Ghia P; Gökbuget N; González-Calle V; Huntly B; Jäger U; Latino NJ; Douillard JY; Malcovati L; Mateos MV; Ossenkoppele GJ; Porkka K; Raderer M; Ribera JM; Scarfò L; Wester R; Zygoura P; Sonneveld P
    ESMO Open; 2020 Jan; 5(1):. PubMed ID: 31958292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0.
    Kiesewetter B; Dafni U; de Vries EGE; Barriuso J; Curigliano G; González-Calle V; Galotti M; Gyawali B; Huntly BJP; Jäger U; Latino NJ; Malcovati L; Oosting SF; Ossenkoppele G; Piccart M; Raderer M; Scarfò L; Trapani D; Zielinski CC; Wester R; Zygoura P; Macintyre E; Cherny NI;
    Ann Oncol; 2023 Sep; 34(9):734-771. PubMed ID: 37343663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ESMO-Magnitude of Clinical Benefit Scale version 1.1.
    Cherny NI; Dafni U; Bogaerts J; Latino NJ; Pentheroudakis G; Douillard JY; Tabernero J; Zielinski C; Piccart MJ; de Vries EGE
    Ann Oncol; 2017 Oct; 28(10):2340-2366. PubMed ID: 28945867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for adjuvant radiotherapy in breast cancer.
    Sapir E; Cherny NI; Ennis RD; Smith BD; Smith GL; Marks LB; Corn BW
    ESMO Open; 2023 Jun; 8(3):101206. PubMed ID: 37236087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score.
    Cherny NI; de Vries EGE; Dafni U; Garrett-Mayer E; McKernin SE; Piccart M; Latino NJ; Douillard JY; Schnipper LE; Somerfield MR; Bogaerts J; Karlis D; Zygoura P; Vervita K; Pentheroudakis G; Tabernero J; Zielinski C; Wollins DS; Schilsky RL
    J Clin Oncol; 2019 Feb; 37(4):336-349. PubMed ID: 30707056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.
    Everest L; Shah M; Chan KKW
    JAMA Netw Open; 2019 Jul; 2(7):e196803. PubMed ID: 31290990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies.
    Paluch-Shimon S; Cherny NI; de Vries EGE; Dafni U; Piccart MJ; Latino NJ; Cardoso F
    ESMO Open; 2020 Sep; 5(5):e000743. PubMed ID: 32893189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).
    Cherny NI; Sullivan R; Dafni U; Kerst JM; Sobrero A; Zielinski C; de Vries EG; Piccart MJ
    Ann Oncol; 2015 Aug; 26(8):1547-73. PubMed ID: 26026162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1.
    Knapen DG; Cherny NI; Zygoura P; Latino NJ; Douillard JY; Dafni U; de Vries EGE; de Groot DJ
    ESMO Open; 2020 Sep; 5(5):e000681. PubMed ID: 32893188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring.
    Gyawali B; de Vries EGE; Dafni U; Amaral T; Barriuso J; Bogaerts J; Calles A; Curigliano G; Gomez-Roca C; Kiesewetter B; Oosting S; Passaro A; Pentheroudakis G; Piccart M; Roitberg F; Tabernero J; Tarazona N; Trapani D; Wester R; Zarkavelis G; Zielinski C; Zygoura P; Cherny NI
    ESMO Open; 2021 Jun; 6(3):100117. PubMed ID: 33887690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?
    Cheng S; McDonald EJ; Cheung MC; Arciero VS; Qureshi M; Jiang D; Ezeife D; Sabharwal M; Chambers A; Han D; Leighl N; Sabarre KA; Chan KKW
    J Clin Oncol; 2017 Aug; 35(24):2764-2771. PubMed ID: 28574778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit.
    Oosting SF; Barriuso J; Bottomley A; Galotti M; Gyawali B; Kiesewetter B; Latino NJ; Martinelli F; Pe M; Pentheroudakis G; Roitberg F; Vachon H; de Vries EGE; Piccart M; Cherny NI;
    Ann Oncol; 2023 Apr; 34(4):431-439. PubMed ID: 36549587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical benefit of cancer drugs approved in Switzerland 2010-2019.
    Adam R; Tibau A; Molto Valiente C; Šeruga B; Ocaña A; Amir E; Templeton AJ
    PLoS One; 2022; 17(6):e0268545. PubMed ID: 35687539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analyzing the clinical benefit of newer therapies for advanced or metastatic non-small-cell lung cancer: application of the ESMO-magnitude of clinical benefit scale v1.1.
    García-Fumero R; Fernández-López C; Calleja-Hernández MÁ; Expósito-Hernández J
    Acta Oncol; 2021 Sep; 60(9):1225-1232. PubMed ID: 34184595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna.
    Kiesewetter B; Raderer M; Prager GW; Fuereder T; Marosi C; Preusser M; Krainer M; Locker GJ; Brodowicz T; Zielinski CC
    ESMO Open; 2017; 2(3):e000166. PubMed ID: 28761758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five years of EMA-approved systemic cancer therapies for solid tumours-a comparison of two thresholds for meaningful clinical benefit.
    Grössmann N; Del Paggio JC; Wolf S; Sullivan R; Booth CM; Rosian K; Emprechtinger R; Wild C
    Eur J Cancer; 2017 Sep; 82():66-71. PubMed ID: 28648700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework.
    de Hosson LD; van Veenendaal LM; Schuller Y; Zandee WT; de Herder WW; Tesselaar MET; Klümpen HJ; Walenkamp AME
    Ann Oncol; 2017 Dec; 28(12):3022-3027. PubMed ID: 29045525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules.
    Dafni U; Karlis D; Pedeli X; Bogaerts J; Pentheroudakis G; Tabernero J; Zielinski CC; Piccart MJ; de Vries EGE; Latino NJ; Douillard JY; Cherny NI
    ESMO Open; 2017; 2(4):e000216. PubMed ID: 29067214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical benefit of systemic therapies for recurrent ovarian cancer-ESMO-MCBS scores.
    Broekman KE; van Kruchten M; van Tinteren H; Sessa C; Jalving M; Reyners AKL
    ESMO Open; 2021 Aug; 6(4):100229. PubMed ID: 34371383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel.
    Hammerman A; Greenberg-Dotan S; Feldhamer I; Birnbaum Y; Cherny NI
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):119-122. PubMed ID: 28617621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.